Teitur Trophics has announced successful results from its phase 1 clinical trial of TT-P34, a first-in-class peptide being developed for Parkinson’s disease.

The study, conducted in healthy volunteers and patients with early-stage Parkinson’s, showed the therapy was safe and well tolerated, with pharmacokinetic data confirming robust central nervous system exposure.

The company said the findings support plans to begin a phase 2 trial in 2027. TT-P34 is designed to improve both mitochondrial and lysosomal function, targeting a pathway implicated in multiple neurodegenerative conditions.

Andreas Borta, Chief Medical Officer at Teitur Trophics, said: “These data show TT-P34 – which is potentially a game-changer not just for Parkinson’s disease but a range of other neurodegenerative diseases as well – has an excellent safety profile and is well tolerated, enters the brain and CNS as expected, and has excellent pharmacokinetics.” He added: “The biomarker data, which indicate engagement of the lysosomal pathway, are also highly encouraging.”

The randomised, double-blind, placebo-controlled trial was carried out at the Centre for Human Drug Research in Leiden. It enrolled 55 healthy volunteers and 12 patients with early-stage Parkinson’s. Once-weekly subcutaneous dosing was safe at all levels tested, including alongside standard levodopa therapy.

Cell Therapies has manufactured and released the first clinical dose for the KOALA trial, marking the start of a first-in-human study evaluating PMCC-COE-KMA in relapsed or refractory multiple myeloma.

The first patient has now been dosed with the investigational therapy developed by the Peter MacCallum Cancer Centre’s Centre of Excellence in Cellular Immunotherapy and licensed by HaemaLogiX.

The trial will assess safety and efficacy in patients whose disease is no longer responding to standard therapies and who are not eligible for other CAR-T treatments. PMCC-COE-KMA targets kappa myeloma antigen, found on myeloma cells but absent from healthy immune cells.

Cell Therapies manufactures clinical doses at its GMP-licensed facility co-located with Peter Mac, enabling a streamlined pathway from research to clinical delivery.
Dr Bev Menner, Chief Executive Officer of Cell Therapies, said: “The successful treatment of the first patient in the KOALA trial is a significant achievement for everyone involved and demonstrates the power of bringing together world-class research, clinical expertise and advanced manufacturing capabilities.”

She added: “Cell Therapies is proud to manufacture the clinical product for this pioneering study and to support the translation of innovative Australian science into potential new treatment options for patients with multiple myeloma.”